The rasH2 Mouse Model for Assessing Carcinogenic Potential of Pharmaceuticals

Toxicologic Pathology

Volumn 41, Issue 8, 2013, Pages 1058-1067

  Nambiar, Prashant R ^a   Morton, Daniel ^a  

^a PFIZER INC   (United States)

Author keywords

carcinogenicity; drug; mice; neoplasia; ras; rasH2

Indexed keywords

ALISKIREN; BAZEDOXIFENE; INDACATEROL; METHYLNITROSOUREA; OLMESARTAN; PALIFERMIN; SUNITINIB; TELBIVUDINE;

ANGIOSARCOMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOASSAY; CARCINOGENICITY; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DUODENUM CARCINOMA; FEMALE; FOOD AND DRUG ADMINISTRATION; GRANULOSA CELL TUMOR; KIDNEY DISEASE; KIDNEY TUMOR; MALE; NONHUMAN; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; RAT; SPLEEN CANCER; STOMACH CARCINOMA; SURVIVAL; TUMOR GROWTH; UTERUS SARCOMA; WEIGHT GAIN;

MUS; RATTUS; RODENTIA;

CARCINOGENICITY; DRUG; MICE; NEOPLASIA.; RAS; RASH2;

ANIMALS; BODY WEIGHT; CARCINOGENICITY TESTS; CELL PROLIFERATION; FEMALE; GENES, RAS; INDOLES; MALE; MICE; MICE, TRANSGENIC; MODELS, ANIMAL; NEOPLASMS, EXPERIMENTAL; PYRROLES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84887576820     PISSN: 01926233     EISSN: 15331601     Source Type: Journal    
DOI: 10.1177/0192623313477257     Document Type: Article

References (29)

1. Adami M. Zamfirova R. Sotirov E. Tashev R. Dobrinova Y. Todorov S. Coruzzi G. (2004). Gastric antisecretory effects of synthetic cannabinoids after central or peripheral administration in the rat. Brain Res Bull 64, 357–61.
2. Akino K. Kondo Y. Ueno A. Yamazaki K. Hosokawa M. Shimoji H. Adachi T. Honda S. Ichiyanagi S. Akahonai Y. Fujisawa Y. Takahashi H. Arimura Y. Endo T. Imai K. (2002). Carcinoma of duodenum arising from Brunner’s gland. J Gastroenterol 37, 293–96.
3. Alden C. Smith P. Morton D. (2002). Application of genetically altered models as replacement for the lifetime mouse bioassay in pharmaceutical development. Toxicol Pathol 30, 135–38.
4. Alden C. L. Lynn A. Bourdeau A. Morton D. Sistare F. D. Kadambi V. J. Silverman L. (2011). A critical review of the effectiveness of rodent pharmaceutical carcinogenesis testing in predicting for human risk. Vet Pathol 48, 772–84.
5. Anonymous. (1998). International conference on harmonization: Guidance on testing for carcinogenicity of pharmaceuticals. Fed Regis 63, 8983–986.
6. Betton G. R. Dormer C. S. Wells T. Pert P. Price C. A. Buckley P. (1988). Gastric ECL-cell hyperplasia and carcinoids in rodents following chronic administration of H2-antagonists SK&F 93479 and oxmetidine and omeprazole. Toxicol Pathol 16, 288–98.
7. Boverhof D. R. Chamberlain M. P. Elcombe C. R. Gonzalez F. J. Heflich R. H. Hernandez L. G. Jacobs A. C. Jacobson-Kram D. Luijten M. Maggi A. Manjanatha M. G. Benthem J. Gollapudi B. B. (2011). Transgenic animal models in toxicology: Historical perspectives and future outlook. Toxicol Sci 121, 207–33.
8. Coruzzi G. Adami M. Coppelli G. Frati P. Soldani G. (1999). Inhibitory effect of the cannabinoid receptor agonist WIN 55,212-2 on pentagastrin-induced gastric acid secretion in the anaesthetized rat. Naunyn-Schmiedeberg’s Arch Pharmacol 360, 715–18.
9. Friedrich A. Olejniczak K. (2011). Evaluation of carcinogenicity studies of medicinal products for human use authorised via the European centralised procedure (1995-2009). Regul Toxicol Pharmacol 60, 225–48.
10. Greaves P. (2012a). Histopathology of preclinical toxicology studies, interpretation and relevance in drug safety evaluation. In Thyroid Gland, p. 776. Elsevier, Amsterdam, The Netherlands.
11. Greaves P. (2012b). Histopathology of preclinical toxicology studies, interpretation and relevance in drug safety evaluation. In Male Genital Tract, p. 652. Elsevier, Amsterdam, The Netherlands.
12. Greaves P. (2012c). Histopathology of preclinical toxicology studies, interpretation and relevance in drug safety evaluation. In Digestive System, p. 383. Elsevier, Amsterdam, The Netherlands.
13. Hagedorn A. Germann P. G. Junker-Walker U. Tomovic A. Seewald W. Polkinghorne A. Pospischil A. (2005). Immunohistochemical study about the Flt-1/VEGFR1 expression in the gastrointestinal tract of mouse, rat, dog, swine and monkey. Exp Toxicol Pathol 57, 149–59.
14. Laine L. Ahnen D. McClain C. Solcia E. Walsh J. H. (2000). Review article: Potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors. Aliment Pharmacol Ther 14, 651–68.
15. Larsson H. Hakanson R. Mattsson H. Ryberg B. Sundler F. Carlsson E. (1988). Omeprazole: Its influence on gastric acid secretion, gastrin and ECL cells. Toxicol Pathol 16, 267–72.
16. Long G. G. Cohen I. R. Gries C. L. Young J. K. Francis P. C. Capen C. C. (2001). Proliferative lesions of ovarian granulosa cells and reversible hormonal changes induced in rats by a selective estrogen receptor modulator. Toxicol Pathol 29, 403–10.
17. Long G. G. Morton D. Peters T. Short B. Skydsgaard M. (2010). Alternative mouse models for carcinogenicity assessment: Industry use and issues with pathology interpretation. Toxicol Pathol 38, 43–50.
18. MacDonald J. French J. E. Gerson R. J. Goodman J. Inoue T. Jacobs A. Kasper P. Keller D. Lavin A. Long G. McCullough B. Sistare F. D. Storer R. van der Laan J. W. (2004). The utility of genetically modified mouse assays for identifying human carcinogens: A basic understanding and path forward. The Alternatives to carcinogenicity testing committee ILSI HESI. Toxicol Sci 77, 188–94.
19. Mendel D. B. Laird A. D. Xin X. Louie S. G. Christensen J. G. Li G. Schreck R. E. Abrams T. J. Ngai T. J. Lee L. B. Murray L. J. Carver J. Chan E. Moss K. G. Haznedar J. O. Sukbuntherng J. Blake R. A. Sun L. Tang C. Miller T. Shirazian S. McMahon G. Cherrington J. M. (2003). In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9, 327–37.
20. Morton D. Alden C. L. Roth A. J. Usui T. (2002). The Tg rasH2 mouse in cancer hazard identification. Toxicol Pathol 30, 139–46.
21. Nambiar P. R. Turnquist S. E. Morton D. (2012). Spontaneous tumor incidence in rasH2 mice: Review of internal data and published literature. Toxicol Pathol 40, 614–23.
22. Pritchard J. B. French J. E. Davis B. J. Haseman J. K. (2003). The role of transgenic mouse models in carcinogen identification. Environ Health Perspect 111, 444–54. Accessed October 2012.
23. Radi Z. A. Morton D. (2012). Human safety risk assessment of lymph node angiomas observed in 2-year carcinogenicity studies in rats. Regul Toxicol Pharmacol 64, 435–41.
24. Ritland S. R. Gendler S. J. Burgart L. J. Fry D. W. Nelson J. M. Bridges A. J. Andress L. Karnes W. E. Jr (2000). Inhibition of epidermal growth factor receptor tyrosine kinase fails to suppress adenoma formation in ApcMin mice but induces duodenal injury. Cancer Res 60, 4678–81.
25. Sistare F. D. Morton D. Alden C. Christensen J. Keller D. Jonghe S. D. Storer R. D. Reddy M. V. Kraynak A. Trela B. Bienvenu J. G. Bjurstrom S. Bosmans V. Brewster D. Colman K. Dominick M. Evans J. Hailey J. R. Kinter L. Liu M. Mahrt C. Marien D. Myer J. Perry R. Potenta D. Roth A. Sherratt P. Singer T. Slim R. Soper K. Fransson-Steen R. Stoltz J. Turner O. Turnquist S. van Heerden M. Woicke J. DeGeorge J. J. (2011). An analysis of pharmaceutical experience with decades of rat carcinogenicity testing: Support for a proposal to modify current regulatory guidelines. Toxicol Pathol 39, 716–44.
26. Suemizu H. Muguruma K. Maruyama C. Tomisawa M. Kimura M. Hioki K. Shimozawa N. Ohnishi Y. Tamaoki N. Nomura T. (2002). Transgene stability and features of rasH2 mice as an animal model for short-term carcinogenicity testing. Mol Carcinog 34, 1–9.
27. Tamaoki N. (2001). The rasH2 transgenic mouse: Nature of the model and mechanistic studies on tumorigenesis. Toxicol Pathol 29 Suppl, 81–89.
28. Tucker M. J. Patterson J. S. Ed. (1984). Safety Testing of New Drugs. Academic Press, London, UK.
29. Witmer A. N. Dai J. Weich H. A. Vrensen G. F. Schlingemann R. O. (2002). Expression of vascular endothelial growth factor receptors 1, 2, and 3 in quiescent endothelia. J Histochem Cytochem 50, 767–77.